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Abstract
Background: The present study was conducted to evaluate the tumor suppressive effects of bone marrow derived
mesenchymal stem cells (MSCs) in an experimental hepatocellular carcinoma (HCC) model in rats and to
investigate the possible role of Wnt signaling in hepato-carcinogenesis.
Methods: Ninety rats were included in the study and were divided equally into: Control group, rats which received
MSCs only, rats which received MSCs vehicle only, HCC group induced by diethylnitroseamine (DENA) and CCl4,
rats which received MSCs after HCC induction, rats which received MSCs before HCC induction. Histopathological
examination and gene expression of Wnt signaling target genes by real time, reverse transcription-polymerase
chain reaction (RT-PCR) in rat liver tissue, in addition to serum levels of ALT, AST and alpha fetoprotein were
performed in all groups.
Results: Histopathological examination of liver tissue from animals which received DENA-CCl4 only, revealed the
presence of anaplastic carcinoma cells and macro-regenerative nodules type II with foci of large and small cell
dysplasia. Administration of MSCs into rats after induction of experimental HCC improved the histopathological
picture which showed minimal liver cell damage, reversible changes, areas of cell drop out filled with stem cells.
Gene expression in rat liver tissue demonstrated that MSCs downregulated b-catenin, proliferating cell nuclear
antigen (PCNA), cyclin D and survivin genes expression in liver tissues after HCC induction. Amelioration of the liver
status after administration of MSCs has been inferred by the significant decrease of ALT, AST and Alpha fetoprotein
serum levels. Administration of MSCs before HCC induction did not show any tumor suppressive or protective
effect.
Conclusions: Administration of MSCs in chemically induced HCC has tumor suppressive effects as evidenced by
down regulation of Wnt signaling target genes concerned with antiapoptosis, mitogenesis, cell proliferation and
cell cycle regulation, with subsequent amelioration of liver histopathological picture and liver function.
Background
Hepatocellular carcinoma (HCC) is a highly prevalent,
treatment-resistant malignancy with a multifaceted
molecular pathogenesis[1]. It is a significant worldwide
health problem with as many as 500,000 new cases diag-
nosed each year[2]. In Egypt, HCC is third among can-
cers in men with >8000 new cases predicted by 2012[3].
Current evidence indicates that during hepatocarcino-
genesis, two main pathogenic mechanisms prevail: cir-
rhosis associated with hepatic regeneration after tissue
damage and mutations occurring in oncogenes or tumor
suppressor genes. Both mechanisms have been linked
with alterations in several important cellular signaling
pathways. These pathways are of interest from a thera-
peutic perspective, because targeting them may help to
reverse, delay or prevent tumorigenesis[1]. In experi-
mental animals interferon-a (IFN-a) gene therapy exerts
significant protective effects, but more so when the gene
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induction in hepatic tissues[4]. In humans, in the
absence of any antiviral response, a course of interferon
alpha does not reduce the risks of liver cancer or liver
failure[5]. Whereas, after curative treatment of primary
tumour; IFN-alpha therapy may be effective for the pre-
vention of HCC recurrence[6]. Therefore providing new
therapeutic modalities may provide a better way for
treatment of HCC and amelioration of tumor mass
prior to surgical intervention.
Advances in stem cell biology have made the pro-
spect of cell therapy and tissue regeneration a clinical
reality[7]. In this rapidly expanding field of cell based
therapy, more attention has been paid to the relation-
ship between stem cells and tumor cells. Qiao and
coworkers reported that human mesenchymal stem
cells (hMSCs) can home to tumor sites and inhibit the
growth of tumor cells[8]. Furthermore, the authors
reported that hMSCs inhibit the malignant phenotypes
of the H7402 and HepG2 human liver cancer cell lines
[9]. The stem cell microenvironment has an essential
role in preventing carcinogenesis by providing signals
to inhibit proliferation and to promote differentiation
[10]. Furthermore, tumor cells may secrete proteins
that can activate signaling pathways which facilitate
hMSC migration to the tumor site [11]. Moreover,
MSCs not only support hematopoiesis, but also exhibit
a profound immune-suppressive activity that targets
mainly T-cell proliferation[12]. In an animal model of
hepatic injury, the researchers suggested that MSCs
m i g h tb e c o m eam o r es u i t a b l es o u r c ef o rS t e mC e l l -
based therapies than hepatic stem cells, because of
t h e i ri m m u n o l o g i c a lp r o p e r t i e sa sM S C sa r el e s s
immunogenic and can induce tolerance upon trans-
plantation[13]. Moreover, MSCs showed the highest
potential for liver regeneration compared with other
BM cell subpopulations [14].
Little is known about the underlying molecular
mechanisms that link MSCs to the targeted inhibition of
tumor cells. Despite their distinct origins, stem cells and
tumor cells share many characteristics[15,16]. In parti-
cular, they have similar signaling pathways that regulate
self-renewal and differentiation[17-20]. The Wnt signal-
ing pathway has been widely investigated in recent
years. It has an important role in stem cell self-renewal
and differentiation, and aberrant activation of the Wnt
signaling pathway has been implicated in human tumor
progression[21]. This has raised the possibility that the
tightly regulated self-renewal process that is mediated
by Wnt signaling in stem cells and progenitor cells may
be subverted in cancer cells to allow malignant prolif-
eration. Wnt signaling regulates genes that are involved
in cell metabolism, proliferation, cell-cycle regulation
and apoptosis[22].
The present work aimed at evaluating the tumor sup-
pressive effects of MSCs on the in vivo progression of
HCC, and to investigate the possible role of Wnt signal-
ing in tumor tissues by assessing the gene expression
profile of some of the Wnt signaling target genes:cyclin
D, PCNA, survivin, b-catenin.
Methods
Ninety albino female rats inbred strain (Cux1: HEL1) of
matched age and weight (6 months-1 year & 120-150
gm) were included in the study. Animals were inbred in
the experimental animal unit, Faculty of Medicine, Cairo
University. Rats were maintained according to the stan-
dard guidelines of Institutional Animal Care and Use
Committee and after Institutional Review Board
approval. Animals were fed a semi-purified diet that
contained (gm/kg): 200 casein, 555 sucrose, 100 cellu-
lose, 100 fat blends, 35 vitamin mix, and 35 mineral mix
[23]. They were divided equally into the following
groups:1
st control rats group, 2
nd group received MSCs
only (3 × 10
6 cells intravenously), 3
rd group received
MSCs solvent, 4
th HCC group induced by diethyl-nitro-
seamine (DENA) and CCl4,5
th g r o u pr e c e i v e dM S C s
after induction of HCC, 6
th group received MSCs before
induction of HCC.
Preparation of BM-derived MSCs
Bone marrow was harvested by flushing the tibiae and
femurs of 6-week-old white albino male rats with Dul-
becco’s modified Eagle’s medium (DMEM, GIBCO/BRL)
supplemented with 10% fetal bovine serum (GIBCO/
BRL). Nucleated cells were isolated with a density gradi-
ent [Ficoll/Paque (Pharmacia)] and resuspended in com-
plete culture medium supplemented with 1% penicillin-
streptomycin (GIBCO/BRL). Cells were incubated at 37°
C in 5% humidified CO2 for 12-14 days as primary cul-
ture or upon formation of large colonies. When large
colonies developed (80-90% confluence), cultures were
washed twice with phosphate buffer saline (PBS) and
the cells were trypsinized with 0.25% trypsin in 1 mM
EDTA (GIBCO/BRL) for 5 min at 37°C. After centrifu-
gation, cells were resuspended with serum-supplemen-
ted medium and incubated in 50 cm
2 culture flasks
(Falcon). The resulting cultures were referred to as first-
passage cultures[24]. On day 14, the adherent colonies
of cells were trypsinized, and counted. Cells were identi-
fied as being MSCs by their morphology, adherence, and
their power to differentiate into osteocytes[25] and
chondrocytes[26]. Differentiation into osteocytes was
achieved by adding 1-1000 nM dexamethasone, 0.25
mM ascorbic acid, and 1-10 mM beta-glycerophosphate
to the medium. Differentiation of MSCs into osteoblasts
was achieved through morphological changes, Alzarin
red staining of differentiated osteoblasts and RT-PCR
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Differentiation into chondrocyte was achieved by adding
500 ng/mL bone morphogenetic protein-2 (BMP-2;
R&D Systems, USA) and 10 ng/ml transforming growth
factor b3( T G F b3) (Peprotech, London) for 3 weeks[26].
In vitro differentiation into chondrocytes was confirmed
by morphological changes, Alcian blue staining of differ-
entiated chondrocytes and RT-PCR of Collagen II gene
expression in cell homogenate. Total RNA was isolated
from the differentiated MSCs using Trizol (Invitrogen,
USA). RNA concentrations were measured by absor-
bance at 260 nm with a spectrophotometer, and 2 μg
total RNA was used for reverse transcription using
Superscript II reverse transcriptase (Invitrogen, USA).
The cDNA was amplified using Taq Platinum (Invitro-
gen, USA). Osteonectin gene and collagen (II) primers
used were designed according to the following oligonu-
cleotide sequence: sense, 5’-GTCTTCTAGCTTCTG
GCTCAGC-3’;a n t i s e n s e , 5 ’-GGAGAGCTGCTTCTCC
CC-3’ (uniGene Rn.133363) and sense, 5’-CCGTGCTTC
TCAGAACATCA-3’;a n t i s e n s e ,5 ’-CTTGCCCCATT
CATTTGTCT-3’ (UniGene Rn.107239). The RNA tem-
plates were amplified at 33 to 45 cycles of 94°C (30 sec),
58°C to 61°C (30 sec), 72°C (1 min), followed with 72°C
for 10 min. PCR products were visualised with ethidium
bromide on a 3% agarose gel. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was detected as house-
keeping gene to examine the extracted RNA integrity.
CD29 gene expression was also detected by RT-PCR as
a marker of MSCs [27].
Preparation of HCC Model
Hepatocarcinogenesis was induced chemically in rats by
injection of a single intraperitoneal dose of diethylnitro-
samine at a dose of 200 mg/kg body weight followed by
weekly subcutaneous injections of CCl4 at a dose of 3
mL/kg body weight for 6 weeks [28,29]. At the planned
time animals were sacrificed by cervical dislocations,
blood samples and liver tissues were collected for assess-
ment of the following:
1. Histopathological examination of liver tissues.
2. Gene expressions by qualitative and quantitative
real time PCR for the following genes: b-catenin, PCNA,
cyclin D and survivin genes
3. Alpha fetoprotein by ELISA (provided by Diagnostic
Systems Laboratories, Inc., Webstar, Texas, USA.)
PCR detection of male-derived MSCs
Genomic DNA was prepared from liver tissue homoge-
nate of the rats in each group usingWizard
® GenomicD-
NApurification kit (Promega, Madison, WI, USA). The
presence or absence of the sex determination region on
the Y chromosome male (sry) gene in recipient female
rats was assessed by PCR. Primer sequences for sry gene
(forward 5’-CATCGAAGGGTTAAAGTGCCA-3’,
reverse 5’-ATAGTGTGTAG-GTTGTTGTCC-3’)w e r e
obtained from published sequences[30,31] and amplified
a product of 104 bp. The PCR conditions were as fol-
lows: incubation at 94°C for 4 min; 35 cycles of incuba-
tion at 94°C for 50 s, 60°C for 30 s, and 72°C for 1 min;
with a final incubation at 72°C for 10 min. PCR pro-
ducts were separated using 2% agarose gel electrophor-
esis and stained with ethidium bromide.
Labeling stem cells with PKH26
PKH26 is a red fluorochrome. It has excitation (551 nm)
and emission (567 nm) characteristics compatible with
rhodamine or phycoerythrin detection systems. The lin-
kers are physiologically stable and show little to no toxic
side-effects on cell systems. Labeled cells retain both
biological and proliferating activity, and are ideal for in
vitro cell labeling, in vitro proliferation studies and long
term, in vivo cell tracking. In the current work, undiffer-
entiated MSCs cells were labeled with PKH26 according
to the manufacturer’s recommendations (Sigma, Saint
Louis, Missouri, USA). Cells were injected intravenously
into rat tail vein. After one month, liver tissue was
examined with a fluorescence microscope to detect the
cells stained with PKH26. Fluorescence was only
detected in the 5th rat group.
Real-time quantitative analyses for b-catenin,PCNA,cyclin
D and survivin genes expression
Total RNA was extracted from liver tissue homogenate
using RNeasy purification reagent (Qiagen, Valencia,
CA). cDNA was generated from 5 μgo ft o t a lR N A
extracted with 1 μl (20 pmol) antisense primer and 0.8
μl superscript AMV reverse transcriptase for 60 min at
37°C. Quantitation of gene expression was conducted
using universal probe library sets based real time PCR
(Roche diagnostics). Selection of genes specific probes
and primers were done using the online ProbeFinder
software and the real time PCR design assay of Roche
Diagnostics found their website: http://www.universal-
probelibrary.com, Hypoxanthine phosphoribosy-ltrans-
ferase 1 (Hprt1) was used as a positive control house
keeping gene. FastStart Universal Probe Master mix was
used in LightCycler
® 480 Instrument (Roche Applied
Science, Indianapolis, USA). Briefly, in the LightCycler
®
480, a total reaction volume of 20 μl was prepared, of
which 2 μl of starting RNA material was included for
RT-PCR, a final concentration of 0.5 μMo fe a c hf o r -
ward and reverse primer and 0.2 μMo ft h eT a q M a n
probe was used. Cycling conditions involve reverse tran-
scription at 50°C for 30 min; enzyme activation at 95°C
for 15 min, followed by 50 cycles of 95°C for 10 sec and
60°C for 60 sec. LightCycler
® 480 RT-PCR data were
analyzed using LightCycler1.2 version 3.5 software using
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amplified targets are expressed in Ct values, or the cycle
at which the target amplicon is initially detected above
background fluorescence levels as determined by the
instrument software. Each sample RT-PCR was per-
formed minimally in duplicate, and the mean Ct value
with standard deviation reported.
Primer sequences:
1-Beta-Catenin:
- left: acagcactccatcgaccag
- right: ggtcttccgtctccgatct
2-CyclinD:
- left: ttcctgcaatagtgtctcagttg
- right: aaagggctgcagctttgtta
3-PCNA:
- left: gaactttttcacaaaagccactc
- right: gtgtcccatgtcagcaatttt
4-Survivin:
- left: gagcagctggctgcctta
- right: ggcatgtcactcaggtcca
Analysis of liver Pathology
Liver samples were collected into PBS and fixed over-
night in 40 g/Lparaformaldehyde in PBS at 4°C. Serial 5-
μm sections of the right lobes of the livers were stained
with hematoxylin and eosin (HE) and were examined
histopathologically.
Results
MSCs culture and identification
Isolated and cultured undifferentiated MSCs reached 70-
80% confluence at 14 days (Figure 1). In vitro osteogenic
and chondrogenic differentiation of MSCs were con-
firmed by morphological changes and special stains (Fig-
ure 2a,b and Figure 3a,b respectively) in addition to
gene expression of osteonectin and collagen II (Figure
4a&4b) and GADPH (Figure 4c).
Histopathology of liver tissues of the animals that
received DENA and CCl4 only showed cells with neo-
plastic changes, anaplastic carcinoma cells, characterized
by large cells with eosinophilic cytoplasm, large hyper-
chromatic nuclei and prominent nucleoli (Figure 5) and
macroregenerative nodules typeII (borderline nodules)
with foci of large and small cell dysplasia (Figure 6).
Improvement of histopathological picture after the
administration of MSCs into rats with HCC is demon-
strated in figure(7); with minimal reversible liver cell
damage in form of ballooning degeneration, areas of cell
drop out filled with stem cells, normal areas with sinu-
soidal dilatation and congestion and absence of fibrous
thickening of portal tracts, inflammation, dysplasia and
absence of regenerative nodules. Figure (8) shows MSCs
labeled with PKH26 fluorescent dye detected in the
hepatic tissue, confirming that these cells homed into
the liver tissue. Data obtained from the group which
received MSCs only and the one which received MSCs
solvent were similar to data obtained from healthy con-
trols. On the other hand, HCC rat group and the rat
group injected with stem cells prior to induction of
HCC (the prophylactic group) showed significant
increase in gene expression of all four genes when com-
pared to controls (p < 0.05) (Figure 9), whereas no sig-
nificant difference in the gene expression was detected
in liver tissues of MSCs-treated HCC rats and control
group. As regards serum levels of alpha fetoprotein (Fig-
ure 10), as well as ALT and AST (Figure 11); significant
increase was found in HCC and the prophylactic group
(p < 0.05), whereas no significant difference was
detected in the HCC rats group treated with MSCs
when compared to the control group.
Discussion
Hepatocellular carcinoma (HCC) is considered as a dis-
ease of dysfunction of the stem cells [32]. Stem cells
and tumor cells share similar signaling pathways that
regulate self-renewal and differentiation, including the
Wnt, Notch, Shh and BMP pathways that determine the
diverse developmental fates of cells [17-20,33,34]. There-
fore, understanding these signaling cascades may pro-
vide insights into the molecular mechanisms that
underlie stemness and tumorigenesis. In the present
study, histopathological examination of liver tissues of
t h ea n i m a l sg r o u pt h a tr e c e i v e dD E N Aa n dC C l 4w a s
the only one which revealed development of HCC (Fig-
ure 1,2). On the other hand, administration of MSCs
into rats after induction of experimental HCC led to
improvement of histopathological picture with minimal
reversible liver cell damage in form of ballooning degen-
eration, areas of cell drop out filled with stem cells, nor-
mal areas with sinusoidal dilatation and congestion and
absence of fibrous thickening of portal tracts, inflamma-
tion, dysplasia and regenerative nodules. These results
reinforce the suggestion of previous studies using animal
models which indicated that mesenchymal cells would
Figure 1 Undifferentiated mesenchymal stem cells after 2
weeks in culture. (×20)
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the studies which drew attention to the potential of
MSCs in regenerative medicine [38].
MSCs were identified by detection of CD29 surface
marker, their fusiform shape, adherence, and their ability
to differentiate into osteocytes and chondrocytes. Hom-
ing of MSCs in liver was confirmed through detection
of Y chromosome-containing cells in samples from
female recipients of bone marrow cells from male
donors, as well as the detection of MSCs labeled with
PKH26(Figure 4). Experimental findings in animal mod-
els suggest that the induction of parenchymal damage is
a prerequisite for successful homing and repopulation
with stem cells [39,40]. Molecular mechanisms underly-
ing stem cells mobilization and homing into the injured
liver are still poorly understood[41]. However, potential
factors and leading pathways have been characterized in
these processes, such as the Stromal Cell-Derived Fac-
tor-1 (SDF-1)/CXCR4 axis, the proteolytic enzymes
matrix metalloproteinases (MMPs), the hepatocyte
growth factor (HGF) and the stem cell factor (SCF). The
chemokine Stromal Cell-Derived Factor-1 (SDF-1) is a
powerful chemo-attractant of hepatic stem cells (HSCs)
[42] which plays a major role in the homing, migration,
proliferation, differentiation and survival of many cell
types of human and murine origin [43]. It is expressed
by various bone marrow stromal cell types and epithelial
cells in many normal tissues, including the liver [44].
SDF-1 carries on its role through the CXCR4 receptor, a
G-protein coupled receptor, expressed on CD34+ hema-
topoietic stem cells, mononuclear leucocytes and
numerous stromal cells [45,46]. Kollet and co-workers
[47] also showed that CCl4-induced liver injury (which
was the case in the present study)resulted in increased
activity of the enzyme MMP-2 and emergence of MMP-
9 in the liver of NOD/SCID mice.
As for the mechanisms by which liver regeneration
occurs after bone marrow cells transfusion, many
mechanisms have been suggested: fusion between hepa-
tocytes and transplanted bone marrow cells has been
substantiated as a mechanism by which hepatocytes that
carry a bone marrow tag are generated[48], although
many studies suggested that cell fusion was not the
main mechanism involved in parenchymal repopulation
with exogenous cells[49,50]. Another mechanism may
be that the stem cells provide cytokines and growth fac-
tors in their microenvironment that promote hepatocyte
functions by paracrine mechanisms[48]. Robert and
coworkers[51] stated that the organ microenvironment
can modify the response of metastatic tumor cells to
therapy and alter the effectiveness of anticancer agents
in destroying the tumor cells without producing
Figure 2 Morphological and histological staining of differentiated BM-MSCs into osteoblasts. (A) (×20) Arrows for differentiated MSCs
osteoblasts after addition of growth factors. (B) (×200) Differentiated MSCs into osteoblasts stained with Alizarin red stain.
Figure 3 Morphological and histological staining of differentiated BM-MSCs into chondrocytes. (A) (×20) Arrows for differentiated MSCs
chondrocytes after addition of growth factors. (B) (×200) Differentiated MSCs into chondrocytes stained with Alcian blue stain.
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coworkers[41] pointed out that, the mechanisms under-
lying the positive effects reported in preliminary trials
are complex and most likely do not involve repopulation
of liver parenchyma with bone marrow-derived cells but
might result from the production of trophic factors by
the infused cells, therefore The identification and char-
acterization of the niche are prerequisites for the identi-
fication of stem cells and for understanding their
behaviour in physiological and pathological conditions.
Niches are local tissue microenvironments that maintain
and regulate stem cells [52], Livraghi and colleagues
[53] stated that the essentialr o l eo fs t e mc e l lm i c r o e n -
vironment in preventing carcinogenesis is by providing
signals to inhibit proliferation and to promote differen-
tiation. Human MSCs home to sites of Kaposi’ss a r -
coma, and potently inhibit tumor growth in vivo by
downregulating Akt activity in tumor cells that are cul-
tured with hMSCs prior to transplantation in animal
tumor models [54]. Furthermore, tumor cells may
secrete proteins that can activate signaling pathways
that facilitate MSCs migration to the tumor site. Direct
transdifferentiation of cells is another mechanism of
liver regeneration, although it has not been demon-
strated [48]. However, recent observations shed some
light on possible mechanisms underlying the observed
bone marrow-derived cells (BMDC) transdifferentiation
driven by injured tissues [55]. As a result of injury, tis-
sues release chemokines attracting circulating BMDC,
and can produce microvescicles including RNA, proteins
and a variety of signals. The authors provided evidence
Figure 4 Agrose gel electrophoresis for Molecular identification of undifferentiated and differentiated BM-MSCs: (A) gene expression of
osteonectin (B) gene expression of collagen II and (C) gene expression of GAPDH in undifferentiated and differentiated MSCs. (A&B) Genes
expression of osteonectin and collagen II. Lane 1: DNA marker (100, 200, 300 bp). Lane 2:No PCR product for osteonectin and Collagen II genes
in undifferentiated MSCs. Lane 3: PCR product for osteonectin and Collagen II genes in differentiated MSCs (C) Gene expression of GAPDH. Lane
1: DNA marker (100, 200, 300 bp). Lane 2: PCR product for GAPDH gene in undifferentiated MSCs
Figure 5 Hepatocellular carcinoma cells. (×400) Characterized by
large anaplastic carcinoma cells with eosinophilic cytoplasm, large
hyperchromatic nuclei and prominent nucleoli. The normal
trabecular structure of the liver is distorted.
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BMDC and can modify cell phenotype mimicking resi-
dent cells in the host tissue. In conclusion, the extensive
work performed during the last decade suggests that a
series of complex interactions exist between BMDC and
injured tissues, including the liver. Microvesicles are
mediators of cell reprogramming. Following injury, tis-
sues release chemokines attracting circulating BMDC,
and can produce microvesicles including RNA, proteins
and a variety of signals. Such microvesicles are taken up
by BMDC and can modify cell phenotype mimicking the
one of resident cells in the host tissue. Insults trigger
the release of chemokines from the endothelium indu-
cing adhesion and migration of circulation BMDC into
the liver parenchyma. The liver itself can release power-
ful signals attracting BMDC and probably contributing
to remodeling of their morphology and function. These
BMDC in turn can produce molecular signals improving
Figure 7 Histopathological picture of liver tissues in rat that
received MSCs after induction of hepatoma. Arrows, A: (×200)
No nodularity & liver cells and lobules appear normal with
ballooning degeneration, B: (×400) Normal portal tracts No fibrosis
No inflammation, C: (×400) Area of cell drop out with stem cells, D:
(×400) No nodularity & liver appears normal, few collections of
round to oval stem cells in lobules.
Figure 6 Histopathological picture of liver tissues in
experimental HCC. Arrows, A: (×400) Small and large cell dysplasia,
B: (×200) Macroregenerative nodules type II (borderline nodules)
apparent with foci of small cell dysplasia & Increased mononuclear
cell infiltrates in portal areas, C: (×200) Focal fatty change &
confluent necrosis with active septation, D: (×200) Portal tract
showing increased mononuclear cell infiltrates.
Figure 8 Detection of MSCs labeled with PKH26 fluorescent
dye in liver tissue. MSCs labeled with the PKH26 showed strong
red autofluorescence after transplantation into rats, confirming that
these cells were seeded into the liver tissue.
Figure 9 PCNA, Beta catenin, Survivin and Cyclin D genes
expression by real time PCR. Results are expressed in 10
6 copy
numbers of each gene mRNA (in 100 ng total RNA). Absolute copy
numbers was determined by comparing samples with the standard
curve generated. The mRNA level of each gene was normalized
with the level of HPRT1 mRNA. * Significant difference in
comparison to control (P < 0.05).
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to note that, in the present study, administration of
MSCs before induction of HCC did not show any tumor
suppressive or protective effect. This may be explained
by the exposure of MSCs to the chemical carcinogen;
DENA and failure of recruitment of MSCs to the liver
tissue before exposure to the chemical injury due to the
absence of cytokines that recruit MSCs to sites of injury
[56]. As regards genetic analysis, results of the present
study demonstrated that MSCs downregulated onco-
genes expression(Figure 9), where, b-catenin, PCNA,
cyclin D and survivin genes expression was downregu-
lated in liver tissues of MSCs-treated HCC rats which
are all involved in Wnt/b-catenin pathway;one of the
main oncogenic pathways involved in HCC[57]. The
decreased serum levels of alpha fetoprotein and liver
enzymes in the HCC group treated with MSCs indicate
the amelioration of the malignant status as well as the
liver function of the HCC model.
In recent years, improved knowledge of oncogenic
processes and the signaling pathways that regulate
tumor cell proliferation, differentiation, angiogenesis,
invasion and metastasis has led to the identification of
several possible therapeutic targets that have driven the
development of molecular targeted therapies. These
drugs have showed clinical benefit in patients with var-
ious tumor types, including HCC[1].
A major and early carcinogenic event in the develop-
ment of HCC seems to be the abnormal regulation of the
transcription factor b-catenin, a key component of the
Wnt signaling pathway [58]. In the normal state, the bind-
ing of members of a family of soluble cysteine-rich glyco-
protein ligands, the Wnts, to members of the Frizzled
family of cell-surface receptors results in the activation of
the Wnt signaling pathway. Receptor binding activates
DSH (downstream effector Dishevelled), which conse-
quently prevents phosphorylation of b-catenin by glycogen
synthase kinase-3b and its subsequent ubiquitination and
proteasomal degradation. An ensuing increase in the cyto-
plasmic concentrations of b-catenin results in its translo-
cation from the cytoplasm to the nucleus. Once in the
nucleus, b-catenin acts as a co-activator to stimulate the
transcription of genes and expression of gene products
involved in cell proliferation (e.g: c-Myc, Cyclin-D, PCNA),
angiogenesis (e.g: VEGF), antiapoptosis (e.g: Survivin) and
the formation of extracellular matrix [59].
Interestingly, Schmidt and coworkers[60] suggested
that Iqgap2 acts as a tumor suppressor, and its loss
can lead to b-catenin activation and the development
of HCC, and this finding further implicates b-catenin
as a key driver of HCC. Direct mutation of b-catenin
is not the only route through which the Wnt pathway
can be aberrantly activated in HCC. In their study,
Hoshida and coworkers[61] stated that, from the
three subclasses of HCC that had been characterized,
two of them showed either increased Wnt pathway
activity or increased MYC/AKT pathway activity. In
the present study, overexpression of gene of the Wnt
signaling molecule; b-catenin and its downstream tar-
gets; PCNA, cyclin D and survivin genes in liver tissue
transformed by DENA, together with their downregu-
lation in MSCs treated rats provids evidence that the
Wnt signaling pathway is likely to regulate the inhibi-
tory role of MSCs. Similar suggestions were provided
by Qiao and coworkers[8]. Also, Zhu and coworkers
[62] demonstrated that MSCs have an inhibitory effect
on tumor proliferation by identifiing that DKK-1 (dick-
kopf-1) which was secreted by MSCs, acts as a nega-
tive regulator of Wnt signaling pathway and is one of
the molecules responsible for the inhibitory effect.
Figure 10 Alpha fetoprotein levels in ng/ml. * Significant
difference in comparison to control (P < 0.05).
Figure 11 Serum ALT and AST levels in U/ml.*S i g n i f i c a n t
difference in comparison to control (P < 0.05).
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Wnt-1-mediated signaling as a potential molecular tar-
get in HCC and demonstrated that Wnt-1 was highly
expressed in human hepatoma cell lines and a sub-
group of human HCC tissues compared to paired adja-
cent non-tumor tissues. An anti-Wnt-1 antibody dose-
dependently decreased viability and proliferation of
Huh7 and Hep40 cells over-expressing Wnt-1 and har-
boring wild type b-catenin, but did not affect normal
hepatocytes with undetectable Wnt-1 expression.
Apoptosis was also observed in Huh7 and Hep40 cells
after treatment with anti-Wnt-1 antibody. In these two
cell lines, the anti-Wnt-1 antibody decreased b-cate-
nin/Tcf4 transcriptional activities, which were asso-
ciated with down-regulation of the endogenous b-
catenin/Tcf4 target genes c-Myc, cyclin D1,a n dsurvi-
vin. They also demonstrated that intratumoral injec-
tion of anti-Wnt-1 antibody suppressed in vivo tumor
growth in a Huh7 xenograft model, which was also
associated with apoptosis and reduced c-Myc,cyclin D1
and survivin e x p r e s s i o n s[ 6 3 ] .M S C sc o u l du p r e g u l a t e
the mRNA expression of cell-cycle negative regulator
p21 and apoptosis-associated protease caspase-3,
resulting in a G0/G1 phase arrest and apoptotic cell
death of tumor cells[64]. They also secrete Dickkopf-1
(DKK-1) to suppress the Wnt/b-catenin signaling path-
way, attenuating the malignant phenotype of tumor
cells[65].
However, the effect of human bone marrow derived
MSCs on the growth of tumoral cells is controversial.
HCC was thought to arise from hepatic stem cells; in
their study Ishikawa and colleagues[66], investigated
the malignant potential of hepatic stem cells derived
from the bone marrow in a mouse model of chemical
hepatocarcinogenesis, their results suggested that hepa-
tic stem cells derived from the bone marrow have low
malignant potential, at least in their model.
Regarding their potential therapeutic use in neoplastic
diseases, some studies have suggested that adoptively
transferred MSCs could favor tumor engraftment and
progression in vivo [67]. The deleterious effects could
derive from different MSCs characteristics. MSCs speci-
fically migrate toward sites of active tumorigenesis,
w h e r et h e yc o u l di n t e g r a t et h es p e c i a l i z e dt u m o rn i c h e ,
contribute to the development of tumor-associated
fibroblasts and myofibroblasts[68], stimulate angiogen-
esis[69], and promote the growth and drug resistance of
both solid tumors and hematological malignancies[70].
On the contrary, Secchiero and coworkers[71] stated
that although MSCs release several pro-angiogenic cyto-
kines and promoted the migration of endothelial cells,
they found that MSCs when directly cocultured with
endothelial cells, significant induction of endothelial cell
apoptosis occured. In this respect, their findings are in
agreement with those of other authors who have
demonstrated that MSCs under certain circumstances
might exert anti-angiogenic activity in highly vascular-
ized tumours[72,73], as wella si nn o r m a le n d o t h e l i a l
cell cultures in vitro. Otsu and coworkers[73] stated
that direct MSCs inoculation into subcutaneous melano-
mas in an in vivo tumor model, induced apoptosis and
abrogated tumor growth. These findings showed for the
first time that at high numbers, MSCs are potentially
cytotoxic and that when injected locally in tumor tissue
they might be effective antiangiogenesis agents suitable
for cancer therapy. These controversies can be attribu-
ted to many factors such as ratio of MSCs to cancer
cells, nature of tumour cells and cancer stem cells,
integrity of immune system, number of stem cell pas-
sages and site of injection; all can affect the outcome of
MSCs use in malignancy. Therefore, the “lack of repro-
ducibility” pointed out by some authorities [74] is at
least partially due to large experimental differences in
published work. There is thus obvious need for a joined
effort by researchers in the field in order to standardize
models and procedures both in vitro and in vivo [75].
Several novel findings regarding the role of MSCs in
cancer development and/or therapy are summarized
from several studies [76,77]: MSCs can behave as potent
antigen-presenting cells (APCs) and could be exploited
as a new therapeutic tool in cancer therapy in order to
amplify immune responses against tumor-specific anti-
gens [12]. Lu and coworkers[78] demonstrated that
MSCs had potential inhibitory effects on tumor cell
growth in vitro and in vivo without host immunosup-
pression, by inducing apoptotic cell death and G0/G1
phase arrest of cancer cells.
On the basis of the previously reported preclinical
data, BM cells seem to facilitate liver regeneration
mainly by a microenvironment modulation, which is
likely to be transitory. In such a case, multiple treat-
ments would presumably be required to achieve signifi-
cant and lasting clinical results; technical issues that
need to be addressed regard the surface antigens used
for MSCs purification, the route of delivery, the amount
of infused cells and the timing of infusions[79].
Conclusions
In conclusion, the present findings demonstrate that
MSCs have tumor suppressive effects in chemically
induced hepatocarcinogenesis as evidenced by down regu-
lation of Wnt signaling target genes concerned with antia-
poptosis, mitogenesis, cell proliferation and cell cycle
regulation. Therefore, Wnt signaling might be considered
as an important pathway in MSCs-mediated targeting of
tumor inhibition. Further studies are recommended
regarding the study of different molecular signaling path-
ways and the precise biologic characteristics of MSCs.
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Page 9 of 11Thorough evaluation of MSCs potential risks versus bene-
fits in malignancy still need to be explored.
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